Facebook
X
LinkedIn
ForwardRSV Prevention in Infants and Young Children: Empowering Pediatric NPs to Lead Early Protection
1.0 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and for non- members.
RSV remains a leading cause of serious illness in infants and young children—but prevention has entered a new era. With long-acting monoclonal antibodies and maternal vaccination now available, healthcare professionals have powerful tools to reduce severe disease and hospitalizations. This engaging activity equips pediatric NPs with the knowledge and confidence to navigate the evolving RSV prevention landscape—covering the latest evidence, safety and efficacy data, and current immunization guidance for infants and young children. Participants will also strengthen their ability to integrate immunoprophylaxis into care plans and communicate effectively with parents and caregivers to support informed shared decision-making.
Educational Partner
This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.
Support Statement
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the CE posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. If a satisfactory score on the posttest is achieved, NAPNAP will issue a NAPNAP CE Contact Hours Certificate.
Copyright Statement
CE Questions?
Contact us at
Contact us at [email protected]
Target Audience
This educational activity is intended for nurse practitioners who provide care for children and adolescents.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
1. Explain the burden of RSV-related morbidity and mortality among infants and young children at highest-risk for severe disease
2. Assess evidence from recent clinical trials on the safety and efficacy of monoclonal antibodies as novel strategies for RSV prevention in pediatric populations
3. Apply current guidance to develop and implement care plans that ensure appropriate use of RSV monoclonal antibodies for all infants, including best practices for counseling parents and caregivers
Additional Information
| Attachment | Size |
|---|---|
 Downloadable Slides | 2.49 MB |
Faculty:
Asuncion Mejias, MD, PhD
Professor of Pediatrics
Department of Infectious Diseases
St. Jude Children’s Research Hospital
Memphis, Tennessee
Flor M. Muñoz, MD
Associate Professor of Pediatrics,
Infectious Diseases
Molecular Virology and Microbiology
Baylor College of Medicine
Texas Children’s Hospital
Houston, Texas
Financial Disclosures:
Asuncion Mejias, MD, PhD:
Advisory Board for AstraZeneca; Enanta Pharmaceuticals, Inc.; Merck & Co., Inc.; Moderna, Inc.; Pfizer; and Sanofi.
Grant/Research Support from Merck & Co., Inc.
Speaker for Pfizer and Sanofi.
Flor M. Muñoz, MD:
Advisory Board for Merck & Co., Inc. and Pfizer.
Consultant for Sanofi.
Support Statement:
This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA._
Accreditation and Credit Designation
This program is accredited by the National Association of Pediatric Nurse Practitioners (NAPNAP) for 1.0 NAPNAP CE contact hour, of which 0.5 is pharmacology (Rx) content.
This enduring material is approved for 1 year from the date of original release, August 1, 2026 to July 31, 2027.
Available Credit
- 1.00 Contact hours